ArticlePeerJ2025
High-fluorescent cells as a rapid screening tool for malignant effusions.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Elevated levels of high-fluorescent cells (HFCs) in serous effusions often suggest the presence of tumor cells. The purpose of this study was to evaluate the diagnostic value of HFC detection in the differentiation between benign and malignant serous effusions using the Sysmex XN-10 automated hematology analyzer in body fluid mode (BF mode). Methods: Serous effusion specimens, including 702 pleural effusions, 255 ascitic fluid samples and 21 pericardial effusions, were collected from 978 patients at the First Affiliated Hospital with Nanjing Medical University between June 2023 and June 2024. The absolute number (HFC#) and percentage (HFC%) of HFCs were detected using the Sysmex XN-10 automated hematology analyzer. Meanwhile, levels of carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH) and other biomarkers in serous effusions were measured. The diagnostic performance for malignant effusions was evaluated using receiver operating characteristic (ROC) curves. Results: The HFC#, HFC% and CEA levels in the malignant effusion group were significantly higher than those in the benign effusion group (all Conclusion: HFC demonstrates high diagnostic value in identifying malignant serous effusions, especially when used in combination with CEA. As a rapid laboratory parameter based on cellular nucleic acid characteristics, HFC can serve as a useful auxiliary tool for screening malignant effusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.